Patient baseline characteristics
| Characteristic . | Value . |
|---|---|
| Number of patients analyzed | 590 |
| Median age, y (range) | 42 (18-68) |
| Disease | |
| CML | 154 (26) |
| AML | 144 (24) |
| MDS | 103 (17) |
| RA/RARS/RCMD | 35 (6) |
| RAEB | 26 (4) |
| AML from MDS | 42 (7) |
| ALL | 74 (13) |
| NHL | 68 (12) |
| MPD | 17 (3) |
| CLL | 14 (2) |
| HD | 6 (1) |
| Multiple myeloma | 4 (1) |
| CMML | 4 (1) |
| LGL leukemia | 1 (0) |
| NK leukemia | 1 (0) |
| Stage | |
| Untreated | 74 (13) |
| CR1 | 222 (38) |
| Second or later CR | 66 (11) |
| PR | 61 (10) |
| Induction failure | 85 (14) |
| Relapse | 82 (14) |
| Graft source | |
| Bone marrow | 317 (54) |
| Peripheral blood | 269 (46) |
| Cord blood | 4 (1) |
| Match | |
| MRD | 270 (46) |
| MUD | 242 (41) |
| Mismatched | 78 (13) |
| Conditioning | |
| Cy/TBI | 567 (96) |
| Bu/Cy | 22 (4) |
| Other | 1 (0) |
| GVHD prophylaxis | |
| CnI + Mtx ± steroids | 281 (48) |
| CnI + Siro ± Mtx | 198 (34) |
| TCD | 68 (12) |
| Other | 43 (7) |
| Male recipient/female donor | 122 (21) |
| CMV seropositivity | |
| Recipient | 244 (41) |
| Donor | 221 (37) |
| Characteristic . | Value . |
|---|---|
| Number of patients analyzed | 590 |
| Median age, y (range) | 42 (18-68) |
| Disease | |
| CML | 154 (26) |
| AML | 144 (24) |
| MDS | 103 (17) |
| RA/RARS/RCMD | 35 (6) |
| RAEB | 26 (4) |
| AML from MDS | 42 (7) |
| ALL | 74 (13) |
| NHL | 68 (12) |
| MPD | 17 (3) |
| CLL | 14 (2) |
| HD | 6 (1) |
| Multiple myeloma | 4 (1) |
| CMML | 4 (1) |
| LGL leukemia | 1 (0) |
| NK leukemia | 1 (0) |
| Stage | |
| Untreated | 74 (13) |
| CR1 | 222 (38) |
| Second or later CR | 66 (11) |
| PR | 61 (10) |
| Induction failure | 85 (14) |
| Relapse | 82 (14) |
| Graft source | |
| Bone marrow | 317 (54) |
| Peripheral blood | 269 (46) |
| Cord blood | 4 (1) |
| Match | |
| MRD | 270 (46) |
| MUD | 242 (41) |
| Mismatched | 78 (13) |
| Conditioning | |
| Cy/TBI | 567 (96) |
| Bu/Cy | 22 (4) |
| Other | 1 (0) |
| GVHD prophylaxis | |
| CnI + Mtx ± steroids | 281 (48) |
| CnI + Siro ± Mtx | 198 (34) |
| TCD | 68 (12) |
| Other | 43 (7) |
| Male recipient/female donor | 122 (21) |
| CMV seropositivity | |
| Recipient | 244 (41) |
| Donor | 221 (37) |
Values indicate number of patients (%) unless otherwise indicated. Percentages may not add to 100 because of rounding.
CML indicates chronic myelogenous leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MPD, myeloproliferative disease excluding CML and CMML; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; CMML, chronic myelomonocytic leukemia; LGL, large granular lymphocyte; NK, natural killer cell; CR, complete remission; PR, partial remission; MRD, matched related donor; MUD, matched unrelated donor; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; GVHD, graft-versus-host disease; CnI, calcineurin inhibitor (cyclosporine or tacrolimus); Mtx, methotrexate; ±, with or without; Siro, sirolimus; TCD, T-cell depletion; and CMV, cytomegalovirus.